News | January 20, 2008

Clinical Trials Scheduled to Evaluate Human Reovirus’ Role in Treatment of Cancer

January 17, 2008 - The U.S. National Cancer Institute is sponsoring a Phase I/II clinical trial that is expected to start in 2008 for patients with metastatic ovarian, peritoneal, or fallopian tube cancers using Oncolytics' proprietary formulation of the human reovirus, called REOLYSIN.

The reovirus, a naturally occurring virus that does not cause disease in humans, has demonstrated strong anti-cancer activity against many types of cancer cells, including ovarian cancer cells.

"When the reovirus enters cancer cells, it produces thousands of copies of itself, causing the cell to burst," explained Dr. Brad Thompson, CEO of Oncolytics Biotech. But the reovirus can replicate only in cancer cells with mutations along a signaling pathway in the cell called the Ras pathway, while leaving normal cells unharmed. Approximately two thirds of all human cancers express this particular mutation and are therefore a potential target for REOLYSIN treatment.

The clinical trial is being carried out at the Ohio State University Comprehensive Cancer Center and is expected to enroll up to 70 patients with metastatic ovarian, peritoneal, or fallopian tube cancers.

For more information:

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init